Otsuka Pharmaceutical Development & Commercialization, Inc., announced an agreement with research experts from the Columbia University Irving Center Vagelos College of Physicians and Surgeons and Mailman School of Public Health to help support the epidemiological needs of Otsuka Global Pharmacovigilance (GPV) for products, enhanced training, and employee education.
The three-year agreement, through October 2022, draws on the extensive expertise of faculty at Columbia Mailman and the Columbia University Irving Medical Center's Vagelos College of Physicians and Surgeons. Faculty members will work with Otsuka on activities such as post-marketing safety and effectiveness studies, the development of data registries, and investigations of rare exposures and outcomes. Columbia Mailman faculty will also provide executive education to Otsuka's pharmacovigilance and clinical research and development employees, including conducting workshops in epidemiology and biostatistics, journal clubs, seminars, and formal courses.
The expertise and scientific depth of the Columbia University Irving Medical Center faculty will help us enhance the epidemiological support for various Otsuka Global Pharmacovigilance regulatory reports and publications. Patient safety is our highest priority and the knowledge sharing, learning, and scientific exchange resulting from this initiative is consistent with Otsuka's commitment to excellence in pharmacovigilance."
Mirza I. Rahman, MD, MPH, senior vice president and chief global pharmacovigilance officer, Otsuka Pharmaceutical Development & Commercialization, Inc., and a Columbia University Mailman School of Public Health alumnus
Leading Columbia Mailman School's research team is Alfred I. Neugut, MD, PhD, MPH, professor of Epidemiology and Myron M. Studner, professor of Cancer Research in Medicine at the Vagelos College of Physicians and Surgeons. Other members of the Columbia University Irving Medical Center team include Drs. Judith Jacobson, Lambert Lumey, Jason Wright, and Daniel Freedberg.
"Our work with Otsuka is a unique and innovative approach to enhancing drug surveillance and safety efforts," said Dr. Neugut of the Mailman School.